Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis

Recent genetic analyses of paired samples from primary tumours and disseminated tumour cells have uncovered a bewildering genetic disparity. It was therefore proposed that ectopically residing tumour cells disseminate early and develop independently into metastases parallel to the primary tumour. Alternatively, these cells may represent an irrelevant cell population unable to spawn metastases whereas only cells that disseminated late in primary tumour development (which therefore are similar to the primary tumour) will form manifest metastasis. Here, we review comparative analyses of paired samples from primary tumours and disseminated tumour cells or primary tumours and metastases. The data demonstrate a striking disparity, questioning the use of primary tumours as surrogate for the genetics of systemic cancer. In the era of molecular therapies that build upon genetic defects of tumour cells, these data call for a direct diagnostic pathology of systemic cancer.

[1]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[2]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[3]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Campanini,et al.  Breast cancer metastases are molecularly distinct from their primary tumors , 2008, Oncogene.

[5]  I. Petersen,et al.  Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. , 2004, Neoplasia.

[6]  K. Hatakeyama,et al.  Heterogeneity of p53 Mutational Status in Esophageal Squamous Cell Carcinoma , 1998, Japanese journal of cancer research : Gann.

[7]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[8]  Chunlei Wu,et al.  Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis , 2004, Cancer.

[9]  J R Siewert,et al.  Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. , 2000, The American journal of pathology.

[10]  S. Veronese,et al.  Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Rabes,et al.  K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.

[12]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[13]  D. Smith,et al.  p53 Mutations in primary colorectal adenocarcinomas and liver metastases , 1996, The British journal of surgery.

[14]  T. Stephenson,et al.  Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization , 2003, Genes, chromosomes & cancer.

[15]  J. Andersen,et al.  Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases , 2007, Breast Cancer Research and Treatment.

[16]  H. Dai,et al.  No common denominator for breast cancer lymph node metastasis , 2005, British Journal of Cancer.

[17]  P. Bachellier,et al.  Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes , 2007, International journal of cancer.

[18]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[19]  Liang Cheng,et al.  Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis , 2007, Modern Pathology.

[20]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[21]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[22]  H. Höfler,et al.  Molecular Genetic Changes in Metastatic Primary Barrett’s Adenocarcinoma and Related Lymph Node Metastases: Comparison with Nonmetastatic Barrett’s Adenocarcinoma , 2000, Modern Pathology.

[23]  F. Al-Mulla,et al.  Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases , 1999, Genes, chromosomes & cancer.

[24]  A. Russo,et al.  Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.

[25]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[26]  M. Loda,et al.  Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. , 1995, Oncogene.

[27]  B. Haddad,et al.  Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases , 2008, Cytogenetic and Genome Research.

[28]  Wei Zhang,et al.  Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients , 2007, Breast Cancer Research and Treatment.

[29]  Sabine Riethdorf,et al.  Review: Biological relevance of disseminated tumor cells in cancer patients , 2008, International journal of cancer.

[30]  A. Chakraborty,et al.  Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.

[31]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[32]  Liang Cheng,et al.  Clonal origin of lymph node metastases in bladder carcinoma , 2005, Cancer.

[33]  F. Holstege,et al.  Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis. , 2006, Cancer research.

[34]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[35]  J. Shih,et al.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  S. Petersen,et al.  Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases , 2002, Virchows Archiv.

[37]  S. Rha,et al.  Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.

[38]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[39]  F. Bosman,et al.  Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph‐node metastases , 1997, International journal of cancer.

[40]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[41]  I. Petersen,et al.  Chromosomal Alterations in Lung Metastases of Colorectal Carcinomas: Associations with Tissue Specific Tumor Dissemination , 2005, Clinical & Experimental Metastasis.

[42]  A. Ullrich,et al.  Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. , 2008, Cancer cell.

[43]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M W Kattan,et al.  Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  K. Lundholm,et al.  P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection , 2001, Cancer.

[46]  T. Lynch The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[47]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[48]  K. Hunter,et al.  Host genetics influence tumour metastasis , 2006, Nature Reviews Cancer.

[49]  A. Ardizzoni,et al.  Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  D. Tarin,et al.  Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: Clinical implications , 2007, Molecular oncology.

[51]  I. Floriani,et al.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.

[52]  T. Ragg,et al.  Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Izbicki,et al.  Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Rodenhuis,et al.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.

[55]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[56]  Liang Cheng,et al.  Genetically Heterogeneous and Clonally Unrelated Metastases May Arise in Patients With Cutaneous Melanoma , 2007, The American journal of surgical pathology.

[57]  R. Weinberg,et al.  Adaptation versus selection: the origins of metastatic behavior. , 2007, Cancer research.

[58]  A. Schäffer,et al.  Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.

[59]  C. Antonescu Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas , 2008, Modern Pathology.

[60]  B. Deyarmin,et al.  The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer , 2008, Annals of Surgical Oncology.

[61]  R. Eils,et al.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.

[62]  J. Luketich,et al.  Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. , 2002, Cancer research.

[63]  Chi-Hung Lin,et al.  Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases—An analysis by comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[64]  F. Al-Mulla,et al.  Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.

[65]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[66]  G. Schlimok,et al.  Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.